Targeted therapy: selected publications list
Selected recent laboratory research publications
- Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. :
Du Y, Honeychurch J, Glennie M, Johnson P, Illidge T .
Cancer Res. 2007 Feb 1;67(3):1335-43. - Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe.
Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM, Erenpreisa J. BMC Cancer. 2006 Jan 9;6:6. - Segregation of genomes in polyploid tumour cells following mitotic catastrophe.
Erenpreisa J, Kalejs M, Ianzini F, Kosmacek EA, Mackey MA, Emzinsh D, Cragg MS, Ivanov A, Illidge TM.
Cell Biol Int. 2005 Dec;29(12):1005-11. Epub 2005 Nov 28. - Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J, Glennie MJ, Illidge TM.
Cancer Res. 2005 Aug 15;65(16):7493-501 - Induction of CD11b+ Cells by Cyclophosphamide Inhibits Anti-CD40 Based Therapy of Lymphoma. Jamie Honeychurch, Martin J. Glennie, Tim M. Illidge.Cancer Research Aug 15;65(16):7493-501
- Anti-CD40 : Janus or gatekeeper? Tim Illidge 15 October 2005 Volume 106 (8) 2595-6
- A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells Mark S Cragg, Mike Bayne, Alison L Tutt, Ruth R French, Stephen Beers, Karin Havenith, Martin J Glennie, Tim Illidge ; Blood 2004;104(8):2540
- Apparent modulation of CD20 by rituximab: an alternative explanation M Cragg, Bayne M, Johnson P, Illidge T, M Glennie Blood 2004 103(10):3989.
- Antibody induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Yong Du, Jamie Honeychurch, Mike Bayne, Martin Glennie, Peter Johnson, and Tim Illidge Blood 2004 103; 1485
- Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-Cell dependent immunity to B-cell lymphoma; J Honeychurch, M J. Glennie, P W M Johnson, and T M. Illidge Blood. 2003;102(4):1449
- Homologous recombination is linked to endoreduplication cycle and mitotic catastrophe after severe genotoxic damage in p53 mutant cells; A. Ivanov, M Cragg, J. Erenpreisa, D Emzinsh, H. Lukman and T. M. Illidge J. Cell Sci. 2003 Oct 15;116(Pt 20):4095-106
- The importance of antibody-specificity in determining successful treatment of radioimmunotherapy of B-cell Lymphoma; T.M. Illidge, M.S.Cragg, H. McBride, R. French; M.J. Glennie ; 1999 Blood 94 (1) 233-243
- Monoclonal Antibody Therapy of B-cell Lymphomas : Signalling Activity On Tumor cells appears more important than recruitment of effectors; A.Tutt, T. Illidge, J. Honeychurch, H. McBride, C Penfold, D Feron, M. Parkhouse, G.Klaus, M. Glennie; 1998 J Immunology 161:3176.
Selected clinical research publications
- Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation.
Morschhauser F, Illidge T (joint first author ), Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, Hess G, Stein H, Kalmus J, Marcus RE. Blood. 2007 Mar 26; [Epub ahead of print] - Clinical efficacy of zanolimumab (HuMax-CD4): two Phase II studies in refractory cutaneous T-cell lymphoma.
Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ. Blood. 2007 Feb 20; [Epub ahead of print] -
Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer
Du, Y , Illidge T , Ell P. Journal of Clinical Oncology (epub May 2007) -
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Weigert O, Illidge T, Hiddemann W, Dreyling M. Cancer. 2006 Aug 15;107(4):686-95.
- American Society of Hematology December 4-7 2004 - Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL): TM Illidge, MC Bayne, M Zivanovic, Y Du, V Lewington, PW Johnson. Blood 2004 104(11)
- Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for patients with Relapsed/Refactory Diffuse large B-Cell Lymphoma not appropriate for Autologous Stem Cell Transplantation: Results of and Open-Label Phase II trial. F Morschhauser, T Illidge, D Huglo, et al. J. Clin Oncol 2006 – in press
- Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and Motexafin gadolinium (MGd) : results of a randomised Phase III trial Christina A. Meyers, Andrea Bezjak, James Liebmann, Tim Illidge, et al J. Clinical Oncology 2004 22 (1) 157 - 165